Refractory neonatal candidemia and high-dose micafungin pharmacotherapy

Journal of Perinatology

Volumn 29, Issue 11, 2009, Pages 738-743

  Natarajan, G ^a   Lulic Botica, M ^a   Aranda, J V ^a,b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; CANDIDEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ENTERIC FEEDING; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEWBORN INFECTION; NEWBORN MORTALITY; OUTCOME ASSESSMENT; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ASPARTATE AMINOTRANSFERASES; CANDIDIASIS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; DRUG THERAPY, COMBINATION; ECHINOCANDINS; ENTERAL NUTRITION; FEMALE; FUNGEMIA; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; LIPOPEPTIDES; LONG-TERM CARE; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70350764811     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2009.75     Document Type: Review

References (19)

1. Benjamin Jr DK, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006; 117(1): 84-92.
2. Levy I, Shalit I, Askenazi S, Klinger G, Sirota L, Linder N. Duration and outcome of persistent candidaemia in newborn infants. Mycoses 2006; 49(3): 197-201.
3. Chapman RL, Faix RG. Persistently positive cultures and outcome in invasive neonatal candidiasis. Pediatr Infect Dis J 2000; 19 (9): 822-827.
4. Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin Jr DK, Sullivan JE et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008; 52(11): 4043-4049.
5. Hope WW, Mickiene D, Petraitis V, Petratiene R, Kelaher AM, Hughes JE. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: Implications for echinocandin therapy in neonates. J Infect Dis 2008; 197(1): 163-171.
6. Uko S, Soqhier LM, Vega M, Marsh J, Reinersman GT, Herring L et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics 2006; 117(4): 1243-1252.
7. Kovacicova G, Lovaszova M, Hanzen J, Roidova A, Mateicka F, Lesay M et al. Persistent fungemia-risk factors and outcome in 40 episodes. J Chemother 2001; 13(4): 429-433.
8. Cotten CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin Jr DK. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 2006; 118(2): 717-722.
9. Odds FC, Brown AJP, Gow NAR. Antifungal agents: Mechanism of action. Trends Microbiol 2003; 11(6): 272-279.
10. Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Curr Opin Infect Dis 2005; 18(6): 484-489.
11. Odio CM, Araya R, Pinto LE, Castro CE, Vasquez S, Alfaro B et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004; 23(12): 1093-1097.
12. Natarajan G, Lulic-Botica M, Rongkavilit C, Pappas A, Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005; 25(12): 770-777.
13. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24(10): 654-661.
14. Heresi GP, Gerstmann DR, Reed MD, van den Anker JN, Blumer JL, Kovanda L et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25(12): 1110-1115.
15. Santos RP, Sanchez PJ, Mejias A, Benjamin Jr DK, Walsh TJ, Patel S et al. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J 2007; 26(4): 364-366.
16. Smith PB, Walsh TJ, Hope W, Takada A, Kovanda L, Kearns GL. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. E-PAS 2008; 2008: 633761-633766.
17. Andes D, Safdar N. Efficacy of micafungin for the treatment of candidemia. Eur J Clin Microbiol Infect Dis 2005; 24(10): 662-664.
18. Ota Y, Tatsuno K, Okugawa S, Yanagimoto S, Kitazawa T, Fukushima A et al. Relationship between the initial dose of micafungin and its efficacy in patients with candidemia. J Infect Chemother 2007; 13(4): 208-212.
19. Weig M, Brown AJP. Genomics and the development of new diagnostics and anti-Candida drugs. Trends Microbiol 2007; 15(7): 310-317.